BackAEON Biopharma Overview

AEON Biopharma Other Current Liabilities

Track AEON Biopharma's other current liabilities ($4.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$4.93M
↓ 9.32% YoYΔ $-507000.00 vs prior year quarter

Peer average

Loading

AEON Biopharma Other Current Liabilities History

Loading

AEON Biopharma vs. peers: Other Current Liabilities Comparison

Loading

AEON Biopharma Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AEON Biopharma (AEON) FAQ

AEON Biopharma (AEON) currently reports a other current liabilities of $4.9M as of March 2026. That compares with $5.4M in the prior-year period — down 9.3% year over year. Use the charts on this page to explore AEON Biopharma's other current liabilities history and peer comparisons.

AEON Biopharma's other current liabilities decreased from $5.4M to $4.9M — a 9.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AEON Biopharma reported $4.9M in other current liabilities as of March 2026. That compares with $5.4M in the prior-year period — down 9.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $4.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AEON Biopharma, and consider following AEON for alerts when major investors trade the stock.